フルテキストファイル
著者
Saito Hiroaki Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Kono Yusuke Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Murakami Yuki Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 研究者総覧
Kuroda Hirohiko Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine KAKEN
Matsunaga Tomoyuki Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 研究者総覧
Fukumoto Yoji Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 研究者総覧 KAKEN
Osaki Tomohiro Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine KAKEN
Fujiwara Yoshiyuki Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine 研究者総覧 KAKEN
キーワード
gastric carcinoma
peritoneal metastasis
prognosis
recurrence
抄録
[Background] Gastric cancer patients with peritoneal metastasis have an extremely poor prognosis. The aim of the current study was to clarify the predictive factors of a better outcome in gastric cancer patients with peritoneal metastasis.
[Methods] We analyzed the records of 2262 gastric adenocarcinoma patients who underwent gastrectomies at our institution between January 1980 and December 2010.
[Results] The 5-year survival rates for advanced gastric cancer patients with P1 (n = 43), P2 (n = 56), and P3 (n = 36) metastasis were 16.3%, 0%, and 0%, respectively. The prognosis of P1 gastric cancer patients was significantly better than that of either P2 (P = 0.0003) or P3 patients (P < 0.0001). A multivariate analysis identified gross appearance and curability as independent prognostic indicators in P1 gastric cancer patients. In fact, the prognosis was good for patients in whom an R0/1 resection had been performed and with tumors having a gross appearance of other than type 4, with a 40% 5-year survival rate and a 29-month median survival time.
[Conclusion] Our data indicated a good prognosis for P1 patients in whom an R0/1 resection could be performed and with tumors having a gross appearance of other than type 4. Therefore, radical surgery and adequate adjuvant chemotherapy should be performed in these patients.
出版者
Tottori University Faculty of Medicine
資料タイプ
学術雑誌論文
外部リンク
ISSN
1346-8049
書誌ID
AA00892882
掲載誌名
Yonago Acta Medica
最新掲載誌名
Yonago Acta Medica
60
3
開始ページ
174
終了ページ
178
発行日
2017-09-15
著者版フラグ
出版社版
掲載情報
Yonago Acta Medica. 2017, 60(3), 174-178
部局名
医学部・医学系研究科・医学部附属病院
言語
英語